iPremom

Cover Block

Attribute	Value
Company Name	iPremom
Tagline	Develops molecular blood tests for early prediction and diagnosis of pregnancy complications, such as preeclampsia.
Headquarters	Paterna, Spain
Founded	2019
Stage	Seed
Business Model	B2B
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding Label	Seed (total disclosed ~$199,000)

Links

• Website: https://ipremom.com/
• LinkedIn: https://es.linkedin.com/company/ipremom

Summary and Signal

iPremom is a Spanish healthtech startup developing a molecular blood test designed to predict preeclampsia and other pregnancy complications months before clinical symptoms appear. The company's proposition rests on translating a specific academic research program, led by reproductive medicine specialist Carlos Simón, into a commercial diagnostic tool, with initial clinical validation from a large prospective study involving over 9,500 women [iPremom, Jul 2021+].

The founding narrative is anchored in the scientific work of Prof. Carlos Simón, a clinician-entrepreneur with a track record of commercializing reproductive diagnostics, most notably as a founder of Igenomix S.L. [Carlos Simón]. The company's CEO is Alfonso Sánchez Córcoles [LinkedIn]. The core product is a first-trimester blood test analyzing circulating RNA signatures, leveraging high-throughput transcriptomics and machine learning to identify at-risk pregnancies [iPremom]. Its differentiation lies in the early timing of the prediction and the molecular specificity of the biomarker panel [Nature Communications].

Financially, iPremom appears to be in a very early, capital-light phase. Public records indicate a single seed round of approximately $199,000 [Seedtable]. The business model is B2B, targeting sales to hospital systems, obstetric clinics, and diagnostic laboratories. Over the next 12-18 months, the critical watchpoints are the transition from clinical study validation to regulatory clearance and commercial launch, the announcement of any pilot partnerships with healthcare providers, and the company's ability to secure a larger funding round to support that commercialization pathway.

Data Accuracy: YELLOW -- Core product claims and scientific leadership are well-documented; funding amount is cited by one source; founder roles and investor details lack multiple-source corroboration.

Taxonomy Snapshot

Axis	Value
Stage	Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	Western Europe (Spain)
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding	Seed (total disclosed ~$199,000)

Company Overview

Founded in 2019, iPremom operates as a private for-profit entity from the Paterna Technology Park in Valencia, Spain [Orphanet]. The company's founding narrative is anchored in the translation of a specific clinical research program into a commercial diagnostic venture. Its public identity is closely tied to the PREMOM prospective clinical study (NCT04990141), which began patient enrollment around 2021 [iPremom, Jul 2021+].

The scientific leadership is credited to Prof. Carlos Simón, a reproductive medicine specialist with a documented history of founding diagnostic companies, including Igenomix S.L. in 2011 [Carlos Simón]. Dr. Aymara Mas is identified as the company's scientific manager, and Alfonso Sánchez Córcoles is listed as CEO [LinkedIn] [Carlos Simon Foundation]. A seed funding amount of approximately $199,000 has been reported [Seedtable].

Data Accuracy: YELLOW -- Core company details confirmed by Orphanet and company site; leadership roles from LinkedIn and foundation site; seed funding figure from a single secondary source.

The Product and the Stack

Core Product Proposition

iPremom's public-facing proposition is a molecular blood test designed for the early prediction of pregnancy complications, with a primary focus on preeclampsia [iPremom].

Technology and Clinical Validation

The technological wedge is a non-invasive screening tool based on the analysis of circulating cell-free RNA (cfRNA) in maternal blood. The company leverages high-throughput transcriptomics and machine-learning-based biomarker discovery to identify specific RNA signatures associated with pregnancy complications [iPremom]. This approach is validated through the prospective PREMOM clinical study (NCT04990141), which enrolled 9,586 pregnant women across fourteen tertiary hospitals in Spain [Nature Communications]. Recent research indicates the test, administered in the first trimester, can identify women at risk of developing preeclampsia approximately five months before clinical diagnosis [EurekAlert!, Jun 2025]. The same cfRNA profiling is reported to differentiate between preeclampsia subtypes and evaluate organ damage [Nature Communications].

Development Stage and Commercial Path

The product is positioned as an early screening tool. The PREMOM study was designed to assess the sensitivity and specificity of this cfRNA-based method [iPremom, Jul 2021+]. One industry report suggests the screening test could become available in clinical practice within the next year [Inside Precision Medicine].

Data Accuracy: GREEN -- Product claims and study details are confirmed by the company's own materials and peer-reviewed publication.

The Market They Are Entering

The unmet need for early, reliable detection of preeclampsia represents a critical gap in maternal healthcare. Preeclampsia affects an estimated 2-8% of pregnancies globally and is a leading cause of maternal and fetal morbidity and mortality [WHO]. The economic burden is substantial, with one analysis estimating the average incremental cost of a preeclampsia-complicated birth at over $7,000 compared to an uncomplicated delivery [AJOG, 2017].

Demand is driven by converging clinical and economic pressures. From a clinical standpoint, existing screening methods have limited predictive power early in pregnancy. Economically, payers and health systems are incentivized to adopt tools that can reduce the high costs associated with severe preeclampsia cases. The recent publication of positive clinical validation data for cfRNA-based screening adds significant momentum to this driver [Nature Communications].

Regulatory pathways and reimbursement frameworks will be decisive. In Europe, the test will likely require CE marking as an in vitro diagnostic device. Gaining coverage from public and private health insurers will be critical for adoption, a process that will hinge on demonstrating clinical accuracy and cost-effectiveness.

Data Accuracy: YELLOW -- Market sizing relies on analogous public health data and cost studies; specific TAM/SAM for the test is not publicly quantified by third-party analysts.

The Competitive Field

IPremom enters a diagnostic field where the primary competition is not from other startups but from entrenched clinical practice and emerging biomarker tests from larger, diversified life science firms.

Preeclampsia screening today relies on a combination of maternal history, blood pressure monitoring, and proteinuria testing. The first wave of potential commercial competitors includes established diagnostic companies developing blood-based biomarker panels. Firms like Thermo Fisher Scientific and Roche Diagnostics have the resources to develop and commercialize cfRNA or protein-based tests within their broader women's health portfolios [PUBLIC]. A more direct, though not yet commercialized, alternative is the research into the sFlt-1/PlGF ratio [PUBLIC].

IPremom's defensible edge today rests on its proprietary, prospectively validated RNA signature derived from the PREMOM study [Nature Communications]. The edge is further cemented by the scientific leadership of Carlos Simón [Carlos Simón]. However, this edge is perishable. The biomarker signatures themselves could be reverse-engineered or independently discovered by larger players with greater sequencing capacity.

The company's most significant exposure is its lack of commercial infrastructure. It has no disclosed partnerships with diagnostic laboratories or hospital networks to deploy its test. A firm like Quest Diagnostics or Labcorp could immediately use their vast phlebotomy and reporting networks to capture the market. Furthermore, iPremom's focus on a single condition makes it a niche player.

Data Accuracy: YELLOW -- Competitive mapping is inferred from standard industry structure; specific competitor intelligence is not publicly available for this early-stage company.

Opportunity

The prize for iPremom is a first-mover position in a global market for early, non-invasive pregnancy complication screening. The headline opportunity is to become the standard-of-care blood test for first-trimester preeclampsia risk assessment. The PREMOM study demonstrated that a simple first-trimester blood test could identify women at risk of developing preeclampsia five months before clinical diagnosis [EurekAlert!, Jun 2025].

Scenario	What happens	Catalyst	Why it's plausible
EU-IVDR Certification & Rollout	The test receives CE-IVD marking.	Successful completion of the PREMOM study's validation phase.	The company has already conducted the necessary large-scale prospective clinical study [iPremom, Jul 2021+].
Strategic Partnership	A major diagnostics company licenses the IP.	Publication of the PREMOM study results.	Large diagnostics firms actively seek to in-license novel biomarkers for women's health.
Adoption as a Hospital System Standard	A leading health system adopts the test.	A health technology assessment demonstrates cost-effectiveness.	Early prediction can enable preventative interventions, creating a clear economic argument for payers.

Data Accuracy: YELLOW -- The clinical study details and scientific premise are well-documented, but commercial traction, partnership evidence, and detailed market adoption pathways are not yet public.

Sources

1. [iPremom, Jul 2021+] PREMOM Clinical Study | https://ipremom.com/premoms-clinical-study/
2. [iPremom] iPremom - Protecting the lives of mothers and children | https://ipremom.com/
3. [iPremom] About us - iPremom | https://ipremom.com/about/
4. [iPremom] Our scientific background | https://ipremom.com/scientific-background/
5. [Orphanet] Orphanet: iPremom | https://www.orpha.net/en/institutions/institution/692019
6. [LinkedIn] iPremom | LinkedIn | https://es.linkedin.com/company/ipremom
7. [Carlos Simón] Bio - Carlos Simón | https://carlos-simon.com/about-me/bio/
8. [Carlos Simón] Carlos Simón: Gynecologist, Researcher and Professor. | https://carlos-simon.com/
9. [Seedtable] Explore 14 Best Biotech Startups in Spain to watch in 2026. | https://www.seedtable.com/best-biotech-startups-in-spain
10. [Carlos Simon Foundation] Team - Carlos Simon Foundation | https://carlossimonfoundation.com/team/
11. [EurekAlert!, Jun 2025] A simple blood test taken in the first trimester of pregnancy could accurately identify women at risk of developing preeclampsia five months before clinical diagnosis | https://www.eurekalert.org/news-releases/1049848
12. [Nature Communications] Monitoring cfRNA profiles not only aids in predicting the risk of developing preeclampsia but also allows the differentiation of both subtypes of preeclampsia and the evaluation of different organ damage in affected patients, providing insights into their prognosis. The PREMOM study enrolled 9586 pregnant women with singleton pregnancies in fourteen tertiary hospitals in Spain. | https://www.nature.com/articles/s41467-024-50643-z
13. [Inside Precision Medicine] The cfRNA-based screening could become available in clinical practice within the next year. | https://www.insideprecisionmedicine.com/topics/translational-research/cell-free-rna-test-predicts-preeclampsia-early-in-pregnancy/